Diabetes mellitus is a growing health problem in the United States. According to a recent CDC report, as of 2015, 30.3 million Americans (9.4% of the US population) have diabetes. Of these, 90% to 95% are diagnosed with type 2 diabetes (T2D). This number will likely continue to grow, because an estimated 84.1 million Americans have pre-diabetes, putting them at increased risk of T2D development. The manufacturers of the novel combination therapies that enter the market each year hope to simplify medication regimens for patients with T2D and to improve their adherence. Select combination products that were approved in the last few years for T2D are listed in Table 1